This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
BackgroundAbdominal aortic aneurysm (AAA) is a severe aortic disease for which no pharmacological interventions have yet been developed. Colocalization analysis pinpointed 13 proteins with strong evidence of colocalization with AAA. Further investigations are needed to clarify the specific roles of these proteins in AAA pathology.
The term cardiometabolic risk describes the chances that a person has of damaging the cardiovascular system when one or more riskfactors appear together. These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome.
Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.
Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major riskfactor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Primordial prevention is changing the environment around you so you do not develop the riskfactors for heart disease and, by extension, do not get the disease early in life. New obesity medications such as GLP-1 agonists have shown significant reductions in weight in those with a prior heart attack. J Am Heart Assoc.
The study, “Comprehensive Cardiovascular RiskFactor Control with a Mobile Health Cardiovascular Risk Self-Management Program,” highlights the potential use of digital health technology in the comprehensive control of riskfactors for cardiovascular disease (CVD), the leading cause of death and disability in the United States.
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 mg) to reduce the risks of heart attack, stroke, coronary revascularization, and CV death.29 Circulation.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content